Zosano Pharma Corp  

(Public, NASDAQ:ZSAN)   Watch this stock  
Find more results for TROY L. WILSON�
1.82
-0.01 (-0.55%)
Jul 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.65 - 1.98
52 week 1.03 - 9.20
Open 1.84
Vol / Avg. 60,715.00/51,326.00
Mkt cap 20.42M
P/E     -
Div/yield     -
EPS -2.67
Shares 12.01M
Beta     -
Inst. own 51%
Aug 10, 2016
Q2 2016 Zosano Pharma Corp Earnings Release (Estimated) Add to calendar
Jun 22, 2016
Zosano Pharma Corp at ROTH Healthcare Day
May 12, 2016
Q1 2016 Zosano Pharma Corp Earnings Call - Webcast
May 12, 2016
Q1 2016 Zosano Pharma Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -9082.11%
Operating margin - -8566.77%
EBITD margin - -7625.56%
Return on average assets -78.54% -96.89%
Return on average equity -143.89% -433.97%
Employees 39 -
CDP Score - -

Address

34790 Ardentech Ct
FREMONT, CA 94555-3657
United States - Map
+1-510-7451200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability. The Company's short-wear-time transdermal patch consists of an array of titanium microneedles that is coated with its formulation of an approved drug and attached to an adhesive patch. When the patch is applied with its hand-held applicator, the microneedles painlessly penetrate the skin, resulting in rapid dissolution and absorption of the drug coating through the capillary bed. Its product candidates include ZP-Triptan, ZP-Glucagon and ZP-PTH. ZP-PTH is a formulation of teriparatide, a synthetic form of parathyroid hormone. ZP-Glucagon is a formulation of glucagon.

Officers and directors

John P. Walker Chairman of the Board
Bio & Compensation  - Reuters
Konstantinos Alataris Ph.D. President, Chief Executive Officer, Director
Bio & Compensation  - Reuters
Georgia L. Erbez Interim Chief Financial Officer
Age: 49
Bio & Compensation  - Reuters
Eric Scharin Vice President - Technical Operations
Bio & Compensation  - Reuters
Thorsten von Stein M.D.Ph.D. Chief Medical Officer
Bio & Compensation  - Reuters
Joseph P. Hagan Director
Age: 46
Bio & Compensation  - Reuters
Bruce D. Steel Director
Age: 49
Bio & Compensation  - Reuters
Troy E. Wilson Ph.D. J.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
Kleanthis G. Xanthopoulos Ph.D. Independent Director
Age: 57
Bio & Compensation  - Reuters